scholarly journals Alterations of the serum peptidome in renal cell carcinoma discriminating benign and malignant kidney tumors

2012 ◽  
Vol 76 ◽  
pp. 125-140 ◽  
Author(s):  
Erica Gianazza ◽  
Clizia Chinello ◽  
Veronica Mainini ◽  
Marta Cazzaniga ◽  
Valeria Squeo ◽  
...  
2006 ◽  
Vol 130 (12) ◽  
pp. 1865-1870 ◽  
Author(s):  
Brian P. Adley ◽  
Norm D. Smith ◽  
Ritu Nayar ◽  
Ximing J. Yang

Abstract Context.—Birt-Hogg-Dubé (BHD) syndrome is a rare clinicopathologic condition transmitted in an autosomal dominant fashion. This complex entity is characterized by cutaneous fibrofolliculomas, kidney tumors, pulmonary cysts, and spontaneous pneumothorax. Recently, the gene possibly responsible for the clinical manifestations of BHD syndrome has been cloned and characterized. The few reviews of BHD syndrome found in the English literature mostly focus on the skin lesions or genetics, with limited information on other pathologic changes, particularly the kidney lesions. Objective.—To review the literature on this subject with a special emphasis on BHD syndrome-associated renal pathology as well as recent advances in molecular genetic discovery of the BHD syndrome. Data Sources.—We used all data available after performing a literature search using MEDLINE and searching under the headings “Birt-Hogg-Dubé,” “hybrid oncocytic tumors,” and “folliculin.” Conclusions.—The presence of BHD syndrome should be investigated in any patient with multiple bilateral kidney tumors, especially if the predominant histologic type is chromophobe renal cell carcinoma or the so-called hybrid oncocytic tumor. The genetic alteration for BHD syndrome has been mapped to chromosome 17p12q11, and the gene in this region has been cloned and believed to be responsible for the BHD syndrome. The function of the BHD product, called folliculin, is still unknown, although it is speculated to be a tumor suppressor gene. Numerous mutations have been described in the BHD gene. Studies are ongoing to determine the relationship between the BHD gene and development of sporadic renal cell carcinoma and other lesions.


1992 ◽  
Vol 59 (1_suppl) ◽  
pp. 156-159
Author(s):  
S. Invernizzi ◽  
D. Pozza ◽  
G. Longo ◽  
S. Cappoli ◽  
G. Locatelli ◽  
...  

The Authors report their experience on kidney oncocytomas. They found 6 cases of kidney oncocytoma in 140 cases of kidney tumors. In all cases histological slides of neoplastic masses were made with traditional stains, PAS and PAS diastase and with immunohistochemical reaction for keratins (BDK) and vimentin (DAKO clone V9). They describe one of the six cases in which the diagnosis of oncocitary G3 type carcinoma was made, and another of oncocytomatosis with borderline aspects versus oncocytomal renal cell carcinoma.


2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e21138-e21138
Author(s):  
Muhammad Ahsan Siraj ◽  
Christophe Pichon ◽  
Aurelian Radu ◽  
Nicolae Ghinea

e21138 Background: Sunitinib is an antiangiogenic receptor tyrosine kinase inhibitor used to treat advanced metastatic renal cell carcinoma and other types of cancer. Sunitinib is effective in only approx. 70% of clear cell renal cell carcinoma (CCRCC) patients, has significant adverse side effects, and no method is available to predict which patients will not respond. Our purpose was to explore the possibility of introducing an effective prediction method based on a marker of the tumor vasculature, the Follicle Stimulating Hormone Receptor (FSHR). Methods: Using immunohistochemistry on paraffin sections with anti-FSHR monoclonal antibodies we studied by photonic and fluorescence microscopy the expression of FSHR in 50 patients diagnosed with advanced metastatic CCRCC. All patients were subjected to surgery for removal of the primary tumor and were subsequently treated with sunitinib orally for ≥ 3 months with a dose of 50 mg/day for 4 weeks followed by 2 weeks off. After therapy the patients were categorized as “responsive”, “stable”, or “non-responsive” based on the RECIST guidelines. The blood vessel density and the percentage of FSHR-positive vessels were determined by immunofluorescence on sections from the primary tumors removed by surgery, prior to the sunitinib treatment. Von Willebrand factor (vWF) was used as specific endothelial marker. Results: There were no significant differences in the total density of vessels (detected with anti-vWF antibody) among the responsive, stable and non-responsive patients. The percentage of FSHR-stained vessels was on average five fold higher for the patients that responded to the treatment in comparison with the stable group and almost eight fold higher than in the non-responsive group. The percentage allowed the detection of responders with 87-100% sensitivity and specificity. Conclusions: The data suggest that FSHR expression levels in the blood vessels of CCRCC primary tumors can be used to predict, with high sensitivity and specificity, the patients that will respond to sunitinib therapy.


2015 ◽  
Vol 2 (1) ◽  
pp. 25-29 ◽  
Author(s):  
Christina Kaprilian ◽  
Maria Horti ◽  
Kosmas Kandilaris ◽  
Andreas Skolarikos ◽  
Nikolaos Trakas ◽  
...  

Multidrug resistance correlates with unfavourable treatment outcomes in numerous cancers including renal cell carcinoma. The expression and clinical relevance of Glutathione-S-transferase-pi (GST-pi), a multidrug resistance factor, in kidney tumors remain controversial. We analyzed the expression of GST-pi in 60 formalin-fixed, paraffin-embedded renal cell carcinoma samples by immunohistochemistry and compared them with matched normal regions of the kidney. A significantly higher expression of GST-pi was observed in 87% of clear cell carcinoma and 50% of papillary subtypes. GST-pi expression did not correlate with tumor grade or patient survival. GST-pi is unlikely to be a prognostic factor for renal cell carcinoma. However, further studies with large number of samples are warranted to establish the role of GST-pi, if any, in intrinsic or acquired resistance of renal cell carcinoma to conventional treatments. Supplementary files: The supplementary files of this article are found under 'Article Tools' at the left side bar.


2019 ◽  
Vol 15 (3) ◽  
pp. 126-131
Author(s):  
Yu. I. Osmanov ◽  
E. A. Kogan ◽  
L. O. Severgina ◽  
L. M. Rapoport ◽  
N. S. Aleksandrov ◽  
...  

In the structure of oncological morbidity, renal cell carcinoma takes the 10th place among malignant neoplasms. The increase in incidence is observed from the age of 35–40 years and reaches a maximum at the age of 65–70 years. In terms of frequency of occurrence, clear cell renal cell carcinoma is ranked first among all kidney tumors. Meanwhile, due to the high heterogeneity of renal cell carcinomas with clear cytoplasm group, significant differential diagnostic difficulties arise in the morphological verification of these tumors. The article presents all nosological forms of kidney tumors with clear cytoplasm and provides a database of already known immunohistochemical markers for each nosological unit.


2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 4526-4526 ◽  
Author(s):  
Andre Poisl Fay ◽  
Marcella Callea ◽  
Kathryn P. Gray ◽  
Thai Huu Ho ◽  
Jiaxi Song ◽  
...  

2013 ◽  
Vol 67 (1) ◽  
pp. 27 ◽  
Author(s):  
Dzelaludin Junuzovic ◽  
Aleksandra Kerleta ◽  
Izet Masic

2021 ◽  
pp. 478-481
Author(s):  
Christopher Hakim ◽  
Avery Mendelson ◽  
Jalpa Patel ◽  
Julia Greer ◽  
Serge Sorser

Approximately 85% of kidney tumors are renal cell carcinoma (RCC). RCC commonly metastasizes to the lung, bone, and lymph nodes; however, gastric metastasis is exceedingly rare. We present an 86-year-old woman with left-sided RCC with known metastatic disease to the lungs, lymph nodes, and bone, who presented with acute blood loss anemia. After hemodynamic stabilization, esophagogastroduodenoscopy revealed a large infiltrative, polypoid, and ulcerated polyp in the gastric body. After complete polypectomy, histological examination demonstrated gastric mucosa ulcerated by clear-cell carcinoma, compatible with metastatic RCC. Our patient was successfully treated with palliative radiation to the gastric body.


Sign in / Sign up

Export Citation Format

Share Document